前线CLL治疗中的风险分层:护理标准
Eugen Tausch1, Christof Schneider1, Stephan Stilgenbauer1
1Comprehensive Cancer Center Ulm and Division of CLL-Internal Medicine III, Ulm University, Germany.
Hematology. American Society of Hematology. Education Program
|December 7, 2024
概括
像布鲁顿氨酸激酶 (BTK) 和BCL2抑制剂这样的向疗法现在导致慢性淋巴细胞白血病 (CLL) 治疗,超过化疗免疫疗法 (CIT) 并改善生存率,特别是在高风险患者中.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 慢性淋巴细胞白血病 (CLL) 治疗因了解其分子生物学方面的进步而显著发展.
- 关键的信号通路,包括布鲁顿氨酸激酶 (BTK) 和BCL2,现在是治疗策略的核心.
- 化疗免疫疗法 (CIT) 正被向药物取代,成为标准的护理.
研究的目的:
- 评估与化疗免疫疗法 (CIT) 相比,布鲁顿氨酸激酶 (BTK) 和BCL2抑制剂在前线慢性淋巴细胞白血病 (CLL) 治疗中的疗效.
- 评估分子遗传标记物对针对性疗法治疗结果的影响.
- 根据患者特异性因素和不良事件概况指导风险分层和治疗选择.
主要方法:
- 第三阶段临床试验比较BTK和BCL2抑制剂基治疗对CIT.
- 在患者队伍中分析无进展生存 (PFS) 和整体生存 (OS).
- 结果的分层基于高风险的CLL亚组 (不变异的IGHV,del17p,TP53突变).
主要成果:
- 与CIT相比,基于BTK和BCL2抑制剂的疗法显示出较高的无进展生存率和总生存率.
- 这些向性药物在高风险的CLL亚组中显示出特别的益处,使得CIT在这些人群中基本上已经过时了.
- 分子标志物 (IGHV,del17p,TP53) 保持预后和预测价值,即使有针对性的治疗.
结论:
- 向治疗,特别是BTK和BCL2抑制剂,是前线CLL治疗的新标准.
- 基于分子标记的风险分层对于优化前线管理至关重要.
- 患者的特征和不良事件概况需要针对性药物之间进行个性化治疗选择.
更多相关视频
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
21.0K
11:39Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
Published on: October 23, 2019
11.4K
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K